A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma
Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ismail, Salima [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:90 ; year:2014 ; number:1 ; pages:49-57 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.critrevonc.2013.12.003 |
|---|
| Katalog-ID: |
ELV039454959 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV039454959 | ||
| 003 | DE-627 | ||
| 005 | 20230625224940.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2013.12.003 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014017000016.pica |
| 035 | |a (DE-627)ELV039454959 | ||
| 035 | |a (ELSEVIER)S1040-8428(13)00258-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Ismail, Salima |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. | ||
| 520 | |a Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. | ||
| 650 | 7 | |a Systemic therapy |2 Elsevier | |
| 650 | 7 | |a Papillary |2 Elsevier | |
| 650 | 7 | |a Sunitinib |2 Elsevier | |
| 650 | 7 | |a Renal cell carcinoma |2 Elsevier | |
| 650 | 7 | |a Targeted therapy |2 Elsevier | |
| 650 | 7 | |a Sorafenib |2 Elsevier | |
| 650 | 7 | |a Temsirolimus |2 Elsevier | |
| 650 | 7 | |a Metastatic |2 Elsevier | |
| 650 | 7 | |a Non-clear cell |2 Elsevier | |
| 650 | 7 | |a Chromophobe |2 Elsevier | |
| 700 | 1 | |a Meskawi, Malek |4 oth | |
| 700 | 1 | |a Hansen, Jens |4 oth | |
| 700 | 1 | |a Bianchi, Marco |4 oth | |
| 700 | 1 | |a Tian, Zhe |4 oth | |
| 700 | 1 | |a Latour, Mathieu |4 oth | |
| 700 | 1 | |a Graefen, Markus |4 oth | |
| 700 | 1 | |a Montorsi, Francesco |4 oth | |
| 700 | 1 | |a Trinh, Quoc-Dien |4 oth | |
| 700 | 1 | |a Perrotte, Paul |4 oth | |
| 700 | 1 | |a Karakiewicz, Pierre I. |4 oth | |
| 700 | 1 | |a Sun, Maxine |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
| 773 | 1 | 8 | |g volume:90 |g year:2014 |g number:1 |g pages:49-57 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2013.12.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2016 | ||
| 912 | |a GBV_ILN_2048 | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 90 |j 2014 |e 1 |h 49-57 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s i si |
|---|---|
| matchkey_str |
ismailsalimameskawimalekhansenjensbianch:2014----:ciiaapaslfytmcramnotosomtsainnl |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
44.52 |
| publishDate |
2014 |
| allfields |
10.1016/j.critrevonc.2013.12.003 doi GBVA2014017000016.pica (DE-627)ELV039454959 (ELSEVIER)S1040-8428(13)00258-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Ismail, Salima verfasserin aut A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe Elsevier Meskawi, Malek oth Hansen, Jens oth Bianchi, Marco oth Tian, Zhe oth Latour, Mathieu oth Graefen, Markus oth Montorsi, Francesco oth Trinh, Quoc-Dien oth Perrotte, Paul oth Karakiewicz, Pierre I. oth Sun, Maxine oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:90 year:2014 number:1 pages:49-57 extent:9 https://doi.org/10.1016/j.critrevonc.2013.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 90 2014 1 49-57 9 045F 610 |
| spelling |
10.1016/j.critrevonc.2013.12.003 doi GBVA2014017000016.pica (DE-627)ELV039454959 (ELSEVIER)S1040-8428(13)00258-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Ismail, Salima verfasserin aut A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe Elsevier Meskawi, Malek oth Hansen, Jens oth Bianchi, Marco oth Tian, Zhe oth Latour, Mathieu oth Graefen, Markus oth Montorsi, Francesco oth Trinh, Quoc-Dien oth Perrotte, Paul oth Karakiewicz, Pierre I. oth Sun, Maxine oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:90 year:2014 number:1 pages:49-57 extent:9 https://doi.org/10.1016/j.critrevonc.2013.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 90 2014 1 49-57 9 045F 610 |
| allfields_unstemmed |
10.1016/j.critrevonc.2013.12.003 doi GBVA2014017000016.pica (DE-627)ELV039454959 (ELSEVIER)S1040-8428(13)00258-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Ismail, Salima verfasserin aut A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe Elsevier Meskawi, Malek oth Hansen, Jens oth Bianchi, Marco oth Tian, Zhe oth Latour, Mathieu oth Graefen, Markus oth Montorsi, Francesco oth Trinh, Quoc-Dien oth Perrotte, Paul oth Karakiewicz, Pierre I. oth Sun, Maxine oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:90 year:2014 number:1 pages:49-57 extent:9 https://doi.org/10.1016/j.critrevonc.2013.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 90 2014 1 49-57 9 045F 610 |
| allfieldsGer |
10.1016/j.critrevonc.2013.12.003 doi GBVA2014017000016.pica (DE-627)ELV039454959 (ELSEVIER)S1040-8428(13)00258-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Ismail, Salima verfasserin aut A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe Elsevier Meskawi, Malek oth Hansen, Jens oth Bianchi, Marco oth Tian, Zhe oth Latour, Mathieu oth Graefen, Markus oth Montorsi, Francesco oth Trinh, Quoc-Dien oth Perrotte, Paul oth Karakiewicz, Pierre I. oth Sun, Maxine oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:90 year:2014 number:1 pages:49-57 extent:9 https://doi.org/10.1016/j.critrevonc.2013.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 90 2014 1 49-57 9 045F 610 |
| allfieldsSound |
10.1016/j.critrevonc.2013.12.003 doi GBVA2014017000016.pica (DE-627)ELV039454959 (ELSEVIER)S1040-8428(13)00258-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Ismail, Salima verfasserin aut A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe Elsevier Meskawi, Malek oth Hansen, Jens oth Bianchi, Marco oth Tian, Zhe oth Latour, Mathieu oth Graefen, Markus oth Montorsi, Francesco oth Trinh, Quoc-Dien oth Perrotte, Paul oth Karakiewicz, Pierre I. oth Sun, Maxine oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:90 year:2014 number:1 pages:49-57 extent:9 https://doi.org/10.1016/j.critrevonc.2013.12.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 90 2014 1 49-57 9 045F 610 |
| language |
English |
| source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:90 year:2014 number:1 pages:49-57 extent:9 |
| sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:90 year:2014 number:1 pages:49-57 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Systemic therapy Papillary Sunitinib Renal cell carcinoma Targeted therapy Sorafenib Temsirolimus Metastatic Non-clear cell Chromophobe |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
miR-214 in stroma cells and tumor progression |
| authorswithroles_txt_mv |
Ismail, Salima @@aut@@ Meskawi, Malek @@oth@@ Hansen, Jens @@oth@@ Bianchi, Marco @@oth@@ Tian, Zhe @@oth@@ Latour, Mathieu @@oth@@ Graefen, Markus @@oth@@ Montorsi, Francesco @@oth@@ Trinh, Quoc-Dien @@oth@@ Perrotte, Paul @@oth@@ Karakiewicz, Pierre I. @@oth@@ Sun, Maxine @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV019637179 |
| dewey-sort |
3610 |
| id |
ELV039454959 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039454959</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625224940.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2013.12.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014017000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039454959</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(13)00258-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ismail, Salima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Systemic therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Papillary</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Renal cell carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Targeted therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Temsirolimus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastatic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-clear cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chromophobe</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meskawi, Malek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hansen, Jens</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bianchi, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tian, Zhe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latour, Mathieu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Graefen, Markus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montorsi, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trinh, Quoc-Dien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perrotte, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karakiewicz, Pierre I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sun, Maxine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:49-57</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2013.12.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">49-57</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ismail, Salima |
| spellingShingle |
Ismail, Salima ddc 610 bkl 44.52 Elsevier Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma |
| authorStr |
Ismail, Salima |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.52 bkl A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Systemic therapy Elsevier Papillary Elsevier Sunitinib Elsevier Renal cell carcinoma Elsevier Targeted therapy Elsevier Sorafenib Elsevier Temsirolimus Elsevier Metastatic Elsevier Non-clear cell Elsevier Chromophobe |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m m mm j h jh m b mb z t zt m l ml m g mg f m fm q d t qdt p p pp p i k pi pik m s ms |
| hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
| hierarchy_parent_id |
ELV019637179 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV019637179 |
| title |
A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma |
| ctrlnum |
(DE-627)ELV039454959 (ELSEVIER)S1040-8428(13)00258-8 |
| title_full |
A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma |
| author_sort |
Ismail, Salima |
| journal |
miR-214 in stroma cells and tumor progression |
| journalStr |
miR-214 in stroma cells and tumor progression |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
49 |
| author_browse |
Ismail, Salima |
| container_volume |
90 |
| physical |
9 |
| class |
610 610 DE-600 610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ismail, Salima |
| doi_str_mv |
10.1016/j.critrevonc.2013.12.003 |
| dewey-full |
610 |
| title_sort |
a critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma |
| title_auth |
A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma |
| abstract |
Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. |
| abstractGer |
Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. |
| abstract_unstemmed |
Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
| container_issue |
1 |
| title_short |
A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma |
| url |
https://doi.org/10.1016/j.critrevonc.2013.12.003 |
| remote_bool |
true |
| author2 |
Meskawi, Malek Hansen, Jens Bianchi, Marco Tian, Zhe Latour, Mathieu Graefen, Markus Montorsi, Francesco Trinh, Quoc-Dien Perrotte, Paul Karakiewicz, Pierre I. Sun, Maxine |
| author2Str |
Meskawi, Malek Hansen, Jens Bianchi, Marco Tian, Zhe Latour, Mathieu Graefen, Markus Montorsi, Francesco Trinh, Quoc-Dien Perrotte, Paul Karakiewicz, Pierre I. Sun, Maxine |
| ppnlink |
ELV019637179 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.critrevonc.2013.12.003 |
| up_date |
2024-07-06T20:39:22.163Z |
| _version_ |
1803863575405527040 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV039454959</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625224940.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2013.12.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014017000016.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV039454959</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(13)00258-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ismail, Salima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Current guidelines provide most support for the use of temsirolimus in first line therapy for metastatic non-clear cell renal cell carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective of this review is to examine the evidence supporting first line temsirolimus use in patients with metastatic nccRCC as well as alternative first line treatment options. Six studies, that assessed the efficacy of five agents qualified for inclusion. Among recognized treatment options for metastatic nccRCC, mean weighted progression free survival values of 7.9 months for temsirolimus vs. 7.3 for sunitinib vs. 8.5 months for sorafenib vs. ≈4.1 months for erlotinib were recorded based on data from 10, 74, 33 and 51 patients respectively. In conclusion, the data supporting first line temsirolimus for metastatic nccRCC are based on a small patient sample. Sunitinib's efficacy is similar to that of temsirolimus but is based on a bigger patient sample that originates from phase II studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Systemic therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Papillary</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Renal cell carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Targeted therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Temsirolimus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastatic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-clear cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chromophobe</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meskawi, Malek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hansen, Jens</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bianchi, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tian, Zhe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latour, Mathieu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Graefen, Markus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montorsi, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trinh, Quoc-Dien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perrotte, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karakiewicz, Pierre I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sun, Maxine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:49-57</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2013.12.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">49-57</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.402793 |